NRX Pharmaceuticals, Inc. entered into Underwriting Agreement with BTIG, LLC valued at approximately $18.8 million (or $21.6 million, if the Underwriters’ option to purchase additional sh (effective 2026-06-03).
“On June 3, 2026, NRx Pharmaceuticals, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with BTIG, LLC, as representative of the several underwriters listed in Schedule A thereto (the “ Underwriters ”) in connection with a public offering of an aggregate of 5,714,286 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), by the Company at a price to the public of $3.50 per share (the “ Offering ”).”
Listing & Compliance Notices
NRX Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding other (rules 5810(b)).
“assurance that Nasdaq will accept the Company’s plan or that the Company will be able to regain compliance within any extension period granted by Nasdaq or maintain compliance with the other continued listing requirements set forth in the Nasdaq Listing Rules. In accordance with Nasdaq Listing Rule 5810(b), the Company is required to disclose the receipt of the Nasdaq Letter. The Nasdaq Letter has no immediate effect on the listing or trading of the Company’s common stock on Nasdaq, which will continue to trade under the symbol “NRXP.” However, beginning five business days from the date of the”
Auditor Changes
NRX Pharmaceuticals, Inc. engaged Weinberg & Company P.A. as its auditor.
“Engagement of New Independent Registered Public Accounting Firm and Dismissal of Independent Registered Public Accounting Firm On November 20, 2025, the audit committee of the board of directors (the “Audit Committee”) of NRx Pharmaceuticals, Inc. (the “Corporation”) approved the engagement of Weinberg & Company P.A. (“Weinberg”) as the Corporation’s independent registered public accounting firm for the fiscal year ending December 31, 2025. Weinberg had been previously engaged to audit the financial statements of Dura Medical LLC, which had been acquired by Hope Therapeutics, Inc.”
Auditor Changes
NRX Pharmaceuticals, Inc. dismissed Salberg & Company P.A. as its auditor.
“on or around November 24, 2025 the Audit Committee of the Corporation dismissed Salberg & Company P.A.”
M&A Transactions
NRX Pharmaceuticals, Inc. completed an acquisition involving Dura Medical, LLC for a combination of cash, membership interests in HTX Management Company LLC (which are convertible into shares of Hope Therapeutics on a one-for-one basis at the (closed 2025-09-08).
“On September 8, 2025, NRx Pharmaceuticals (NASDAQ: NRXP, or the “Company”), principally through its subsidiary HOPE Therapeutics, Inc., a Delaware corporation, completed its previously announced acquisition of Dura Medical, LLC”
Mike Taylor was appointed as Director at NRX Pharmaceuticals, Inc..
“On January 15, 2025, NRx Pharmaceuticals, Inc. (the “ Company ”) appointed Mike Taylor as a Class I member of the Board of Directors of the Company (“ Board ”).”
Janet Rehnquist resigned as Director at NRX Pharmaceuticals, Inc..
“Mr. Taylor was appointed to fill the seat vacated as a result of the resignation from the Board of Janet Rehnquist on January 7, 2025.”
Janet Rehnquist resigned as member of the Board of Directors at NRX Pharmaceuticals, Inc..
“On January 7, 2025, Janet Rehnquist resigned as a member of the Board of Directors (“ Board ”) of NRx Pharmaceuticals, Inc. (the “ Company ”), effective immediately.”
Richard Narido changed role as Interim Chief Financial Officer at NRX Pharmaceuticals, Inc..
“Mr. Abrams succeeds Interim Chief Financial Officer Richard Narido, who will continue to support the Company’s financial function and other projects.”
Michael Abrams was appointed as Chief Financial Officer at NRX Pharmaceuticals, Inc..
“On November 18, 2024, NRx Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing the appointment of Michael Abrams as the Chief Financial Officer of the Company.”
Jonathan Javitt was appointed as Interim Chief Executive Officer at NRX Pharmaceuticals, Inc..
“Jonathan Javitt, Chairman of the Board of Directors of the Company, was appointed as Interim Chief Executive Officer concurrent with Mr. Willard’s resignation.”
Stephen Willard resigned as Chief Executive Officer at NRX Pharmaceuticals, Inc..
“On October 7, 2024, Stephen Willard, the Chief Executive Officer of NRx Pharmaceuticals, Inc. (the “ Company ”) provided notice to the Board that he was resigning from the Company, effective immediately”
Dr. Dennis McBride was appointed as member of the Board of Directors at NRX Pharmaceuticals, Inc..
“On June 13, 2024, NRx Pharmaceuticals, Inc. (the “ Company ”) appointed Dr. Dennis McBride to serve as a member of the Board of Directors of the Company.”
Earnings Releases
NRX Pharmaceuticals, Inc. reported financial results for quarter ended March 31, 2024.
“NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, the “Company”), a clinical-stage biopharmaceutical company, today announced its financial results for the quarter ended March 31, 2024, and provided a business update.”
Earnings Releases
NRX Pharmaceuticals, Inc. reported financial results for first quarter ending March 31, 2024.
“On May 14, 2024, NRx Pharmaceuticals, Inc. (the “ Company ”) issued a press release announcing its financial results for the first quarter ending March 31, 2024”
Debt Financings
NRX Pharmaceuticals, Inc. faced acceleration on convertible notes of $11,020,000.00 with Streeterville Capital, LLC.
“Note (the "Note") dated November 4, 2022 issued by NRX Pharmaceuticals, Inc., a Delaware corporation ("Borrower"), in favor of Lender, in the original principal amount of $11,020,000.00, as amended by that certain Amendment to Convertible Promissory Note dated March 30, 2023 ("Amendment #1"), that certain Amendment #2 to Convertible Promissory Note dated July”
Material Agreements
NRX Pharmaceuticals, Inc. entered into Underwriting Agreement with EF Hutton LLC valued at approximately $2.0 million (effective 2024-04-18).
“On April 18, 2024, NRx Pharmaceuticals, Inc. (the “ Company ”) entered into an underwriting agreement (the “ Underwriting Agreement ”) with EF Hutton LLC (the “ Representative ”), as the representative of the several underwriters named therein (the “ Underwriters ”), relating to an underwritten public offering (the “ Offering ”) of 607,000 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 per share (“ Common Stock ”).”
Earnings Releases
NRX Pharmaceuticals, Inc. reported financial results for the fourth fiscal quarter and year ending December 31, 2023.
“On April 1, 2024, NRx Pharmaceuticals, Inc. issued a press release announcing its financial results for the fourth fiscal quarter and year ending December 31, 2023 and provided a business update.”
Governance Changes
NRX Pharmaceuticals, Inc.: Amendment to certificate of incorporation to effect a 1-for-10 reverse stock split of common stock, effective April 1, 2024 (effective 2024-04-01).
“On March 28, 2024, NRx Pharmaceuticals, Inc. (the “ Company ”) announced that it had filed with the Secretary of State of the State of Delaware a Certificate of Amendment to the Company’s Second Amended and Restated Certificate of Incorporation (the “ Charter Amendment ”) to effect a 1-for-10 reverse stock split (the “ Reverse Stock Split ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), effective as of 4:30 p.m. Eastern Standard Time on April 1, 2024 (the “ Effective Time ”).”
Shareholder Votes
NRX Pharmaceuticals, Inc. shareholders approved Reverse stock split of all outstanding shares at a ratio in the range of 1-for-2 to 1-for-15 at the 2024-03-21 meeting.
“Proposal 1. The Company’s stockholders approved an amendment to the Company’s Second Amended and Restated Certificate of Incorporation to effect, at the discretion of the Board of Directors of the Company (the “Board”) but prior to the one-year anniversary of the date on which the reverse stock split is approved by the Company’s stockholders at the Special Meeting, a reverse stock split of all of the outstanding shares of the Company’s common stock, $0.001 par value per share, at a ratio in the range of 1-for-2 to 1-for-15, with such ratio to be determined by the Board in its discretion and included in a public announcement.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.